S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)
Key facts
- Who runs it
- Medical University of Warsaw
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 1 Sept 2023
- Ended
- 1 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- S-Adenosyl-L-methionine (SAMe)
- Placebo
- Record updated
- 25 August 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- primary sclerosing cholangitis fulfilling EASL criteria
- age: 18 - 75 years
- treatment with ursodeoxycholic acid (UDCA) in a dose of 13-15mg/kg b.w. for at least 6 months
Who cannot take part
- treatment with: steroids, statins, rifampicin, antidepressants
- patients with other forms of chronic liver diseases
- other diseases or states that can affect quality of life and mood: decompensated diabetes mellitus, renal insufficiency requiring dialyses, malignancy, heart failure ≥ New York Heart Association (NYHA) II, organ transplantation, known HIV infection, rheumatoid arthritis, asthma, psychiatric disorders
- history of hypersensitivity reactions to S-adenosylmethionine
- any other condition, which in the opinion of the investigators would impede the patient's participation or compliance in the study
- inability to give informed consent
- decompensated liver cirrhosis (Child-Pugh class B-C)
- patients with PSC who underwent stenting of their biliary tree within 6 months
- pregnant or breastfeeding women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to investigate clinical effects (liver biochemistries, health-related quality of life, liver stiffness) and underlying mechanisms of hepatoprotection of S-adenosylmethionine in patients with primary sclerosing cholangitis. The study will be performed in a randomized and placebo-controlled fashion.
The 2 groups in the trial
- S-adenosylmethionine (SAMe)Treatment being tested
Participants randomized to SAMe Group will receive S-adenosyl-L-methionine 1200 mg/daily (as 2400mg SAMe disulfate tosylate) in tablets in two divided doses (800mg in the morning and 400mg midday) over the period of 6 months. In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg b.w.
Treatment: S-Adenosyl-L-methionine (SAMe)
- PlaceboPlacebo, for comparison
Patients in Placebo Group will receive a placebo of identical appearance, smell and taste, with the same schedule. In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg.In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg b.w.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Effect and Molecular Mechanisms of Action of S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)
- Record updated
- 25 August 2026